grant
Immune Oncology
Organization CASE WESTERN RESERVE UNIVERSITYLocation CLEVELAND, UNITED STATESPosted 1 Aug 1997Deadline 31 Mar 2030
NIHUS FederalResearch GrantFY2025AchievementAchievement AttainmentAdoptive Cell TransfersAntineoplastic VaccineAreaBasic ResearchBasic ScienceBiometricsBiometryBiostatisticsBody TissuesBone-Derived Transforming Growth FactorCAR T cellsCAR modified T cellsCAR-TCAR-TsCCSGCTLA-8CTLA-8 GeneCTLA8CTLA8 GeneCancer BiologyCancer CenterCancer Center Support GrantCancer PatientCancer TreatmentCancer VaccinesCancersCaringCell BodyCell DeathCell FunctionCell PhysiologyCell ProcessCell TherapyCellsCellular FunctionCellular ImmunologyCellular PhysiologyCellular ProcessChildhood OsteosarcomaClinicClinicalClinical ResearchClinical StudyClinical TrialsCollaborationsColorectal CancerComprehensive Cancer CenterCytometryCytotoxic T-Lymphocyte-Associated Antigen 8Cytotoxic T-Lymphocyte-Associated Antigen 8 GeneCytotoxic T-Lymphocyte-Associated Serine Esterase 8Cytotoxic T-Lymphocyte-Associated Serine Esterase 8 GeneCytotoxic cellDNA mutationDedicationsDendritic CellsDevelopmentDiagnosisDirect CostsDisciplineDiseaseDisorderEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFundingGeneticGenetic ChangeGenetic DeterminismGenetic defectGenetic mutationGenomicsGerminoblastic SarcomaGerminoblastomaGrantHSC transplantationHaplotypesHealthHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoieticHematopoietic CancerHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic Stem Cell TransplantHematopoietic Stem Cell TransplantationHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHistologyIL-1IL-17IL-17 GeneIL-17AIL-17A GeneIL1IL17IL17 ProteinIL17 geneIL17AIL17A GeneImmuneImmune EvasionImmune Modulation TherapyImmune RegulatorsImmune TargetingImmune ToleranceImmune mediated therapyImmune responseImmune systemImmunesImmunogeneticsImmunogenomicsImmunologic ToleranceImmunologically Directed TherapyImmunomodulatorsImmunooncologyImmunotherapeutic agentImmunotherapyInflammasomeInnate ImmunityInstitutionInterleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8)Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8) GeneInterleukin 17 PrecursorInterleukin 17 Precursor GeneInterleukin IInterleukin-1Interleukin-17InternationalInvestigationInvestigatorsJournalsK lymphocyteKeytrudaLeadershipLicensingLiquid substanceLymphocyte-Stimulating HormoneLymphomaMacrophage Cell FactorMagazineMalignant CellMalignant Hematologic NeoplasmMalignant Hematopoietic NeoplasmMalignant LymphomaMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMilk Growth FactorMolecularMolecular ImmunologyMultiple MyelomaMutationMyeloid-derived suppressor cellsNK CellsNative ImmunityNatural ImmunityNatural Killer CellsNeoplasm VaccinesNon-Specific ImmunityNonspecific ImmunityOutcomePathway interactionsPatientsPediatric OsteosarcomaPeer ReviewPhasePlasma-Cell MyelomaPlatelet Transforming Growth FactorProgenitor Cell TransplantationPropertyProtocolProtocols documentationPublicationsPublishingQOLQuality of lifeReceptor ProteinResearchResearch PersonnelResearchersResistanceResource SharingReticulolymphosarcomaRoleScientific PublicationSolidSolid NeoplasmSolid TumorStem Cell TransplantationStem cell transplantSubcellular ProcessT Helper FactorT cells for CART-CellsT-LymphocyteTGF BTGF-betaTGF-βTGFbetaTGFβTissuesTransforming Growth Factor betaTransforming Growth Factor-Beta Family GeneTranslational ResearchTranslational ScienceTranslationsTumor ImmunityTumor VaccinesUnderserved PopulationUnresectableVeiled CellsWorkadaptive immunityadoptive cell therapyadoptive cellular therapyanti-canceranti-cancer therapyanti-tumor immunityanti-tumor vaccineantitumor immunityblood cancerblood stem cell transplantationcancer cellcancer diagnosiscancer immune therapeuticscancer immunitycancer immunotherapeuticscancer microenvironmentcancer of bloodcancer of the bloodcancer therapycancer-directed therapycell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapycheck point blockadecheckpoint blockadechimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical translationclinical trial participantclinically translatabledevelopmentalepigeneticallyfirst in manfirst-in-humanfluidgenetic determinantgenome mutationhematopoietic cell transplantationhematopoietic cellular transplantationhematopoietic progenitor cell transplantationhemopoietichost responseimmune check point blockadeimmune checkpoint blockadeimmune drugsimmune evasiveimmune modulatorsimmune modulatory therapiesimmune modulatory treatmentimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune resistanceimmune system responseimmune system toleranceimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune unresponsivenessimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmune-modulation treatmentimmune-oncologyimmune-resistantimmuno oncologyimmuno therapyimmunologic therapeuticsimmunological paralysisimmunology oncologyimmunomodulation therapyimmunomodulation treatmentimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatory biologicsimmunomodulatory moleculesimmunomodulatory therapiesimmunomodulatory treatmentimmunoreactivityimmunoregulatorimmunoregulatory moleculesimmunoregulatory therapyimmunoregulatory treatmentimmunoresistanceimmunoresponseimmunosuppressive myeloid cellsimmunotherapeuticsimmunotherapy agentimprovedinnovateinnovationinnovativeinsightinvestigator-initiated trialliquidlymphocyte activating factormalignancymanufacturemembermultidisciplinarymyeloid suppressor cellsmyeloid-derived suppressive cellsmyelomamyelomatosisnecrocytosisneoplasm/cancernew approachesnovelnovel approachesnovel strategiesnovel strategyoncoimmunologyoncology programpathwaypembrolizumabpharmacologicpre-clinicalpre-clinical researchpreclinicalpreclinical researchprogenitor transplantationprognosticationprogramsreceptorresistance mechanismresistantresistant mechanismresponseresponse biomarkerresponse markerssmall moleculesocial rolestem and progenitor cell transplantationssuppressive myeloid cellstherapeutic immunomodulationtherapeutic immunoregulationthymus derived lymphocytetranslationtranslation researchtranslational applicationstranslational investigationtumortumor microenvironmentunder served groupunder served individualunder served peopleunder served populationunderserved groupunderserved individualunderserved peoplevaccine for cancerwork groupworking group
Description preview
IMMUNE ONCOLOGY PROGRAM
PROJECT SUMMARY/ABSTRACT
The objectives of the Immune Oncology (IO) Program are to improve cancer diagnosis, care and cure rates
through better understanding of molecular and cellular interplay between cancer cells and the immune system
and optimizing the efficacy of cellular and molecular immunotherapies and stem cell…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click